What is Roth Capital's Estimate for Accuray Q1 Earnings?

Key Points

• Roth Capital estimates that Accuray will report Q1 2027 earnings at ($0.02) per share, with a full-year consensus of $0.01 per share.
• Accuray's stock has decreased by 5.1%, reaching $1.39, and has a market capitalization of $156.01 million.
• Analyst ratings for Accuray have improved, with Wall Street Zen upgrading the stock to a "buy" rating and BTIG raising its target price from $4.00 to $5.00.

Accuray Incorporated (NASDAQ:ARAY - Free Report) - Analysts at Roth Capital issued their Q1 2027 earnings estimates for Accuray in a research note issued on Wednesday, August 13th. Roth Capital analyst J. Wittes forecasts that the medical equipment provider will post earnings of ($0.02) per share for the quarter. The consensus estimate for Accuray's current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray's Q2 2027 earnings at ($0.01) EPS, Q3 2027 earnings at $0.01 EPS and Q4 2027 earnings at $0.03 EPS.

ARAY has been the topic of a number of other research reports. Wall Street Zen upgraded shares of Accuray from a "hold" rating to a "buy" rating in a research report on Friday, May 30th. BTIG Research reissued a "buy" rating and issued a $5.00 target price (up previously from $4.00) on shares of Accuray in a research note on Thursday.

Accuray Trading Down 5.1%

Shares of ARAY traded down $0.08 during mid-day trading on Friday, reaching $1.39. The company's stock had a trading volume of 354,215 shares, compared to its average volume of 759,330. Accuray has a 52 week low of $1.14 and a 52 week high of $2.95. The stock has a market cap of $156.01 million, a PE ratio of -69.25 and a beta of 1.24. The company's fifty day moving average price is $1.34 and its two-hundred day moving average price is $1.63. The company has a current ratio of 1.64, a quick ratio of 0.92 and a debt-to-equity ratio of 3.35.

Accuray (NASDAQ:ARAY - Get Free Report) last announced its earnings results on Wednesday, August 13th. The medical equipment provider reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). Accuray had a negative net margin of 0.35% and a negative return on equity of 5.79%. The company had revenue of $127.54 million for the quarter, compared to the consensus estimate of $123.78 million.

Institutional Investors Weigh In On Accuray

Several institutional investors have recently added to or reduced their stakes in ARAY. Ameriprise Financial Inc. bought a new position in Accuray in the 4th quarter worth $35,000. ProShare Advisors LLC raised its holdings in Accuray by 50.7% in the 4th quarter. ProShare Advisors LLC now owns 27,308 shares of the medical equipment provider's stock worth $54,000 after purchasing an additional 9,187 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Accuray in the 4th quarter worth $66,000. Gabelli Funds LLC grew its position in shares of Accuray by 12.5% in the 4th quarter. Gabelli Funds LLC now owns 45,000 shares of the medical equipment provider's stock worth $89,000 after buying an additional 5,000 shares during the period. Finally, Williams & Novak LLC grew its position in shares of Accuray by 25.5% in the 2nd quarter. Williams & Novak LLC now owns 68,970 shares of the medical equipment provider's stock worth $94,000 after buying an additional 14,000 shares during the period. Hedge funds and other institutional investors own 64.08% of the company's stock.

About Accuray

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.